JP2012515893A5 - - Google Patents

Download PDF

Info

Publication number
JP2012515893A5
JP2012515893A5 JP2011545757A JP2011545757A JP2012515893A5 JP 2012515893 A5 JP2012515893 A5 JP 2012515893A5 JP 2011545757 A JP2011545757 A JP 2011545757A JP 2011545757 A JP2011545757 A JP 2011545757A JP 2012515893 A5 JP2012515893 A5 JP 2012515893A5
Authority
JP
Japan
Prior art keywords
sicam
patient
vector
immunogenic composition
level
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2011545757A
Other languages
English (en)
Japanese (ja)
Other versions
JP2012515893A (ja
JP5379243B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2010/050532 external-priority patent/WO2010084100A1/en
Publication of JP2012515893A publication Critical patent/JP2012515893A/ja
Publication of JP2012515893A5 publication Critical patent/JP2012515893A5/ja
Application granted granted Critical
Publication of JP5379243B2 publication Critical patent/JP5379243B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2011545757A 2009-01-20 2010-01-18 患者を選択するためのバイオマーカーおよびそれに関連する方法 Expired - Fee Related JP5379243B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP09305044.1 2009-01-20
EP09305044 2009-01-20
EP09305294 2009-04-07
EP09305294.2 2009-04-07
PCT/EP2010/050532 WO2010084100A1 (en) 2009-01-20 2010-01-18 Soluble icam-1 as biomarker for prediction of therapeutic response

Publications (3)

Publication Number Publication Date
JP2012515893A JP2012515893A (ja) 2012-07-12
JP2012515893A5 true JP2012515893A5 (https=) 2013-01-17
JP5379243B2 JP5379243B2 (ja) 2013-12-25

Family

ID=42028081

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2011545757A Expired - Fee Related JP5379243B2 (ja) 2009-01-20 2010-01-18 患者を選択するためのバイオマーカーおよびそれに関連する方法

Country Status (23)

Country Link
US (2) US20110312525A1 (https=)
EP (1) EP2382474B1 (https=)
JP (1) JP5379243B2 (https=)
KR (1) KR20110116016A (https=)
CN (1) CN102292638B (https=)
AU (1) AU2010206195B2 (https=)
BR (1) BRPI1006901A2 (https=)
CA (1) CA2749192A1 (https=)
CO (1) CO6390020A2 (https=)
CR (1) CR20110438A (https=)
DK (1) DK2382474T3 (https=)
ES (1) ES2536747T3 (https=)
HR (1) HRP20150470T1 (https=)
HU (1) HUE025015T2 (https=)
IL (1) IL213098A (https=)
MX (1) MX2011007386A (https=)
NZ (1) NZ593749A (https=)
PL (1) PL2382474T3 (https=)
PT (1) PT2382474E (https=)
SG (2) SG196837A1 (https=)
TW (1) TWI440854B (https=)
WO (1) WO2010084100A1 (https=)
ZA (1) ZA201105271B (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103175959B (zh) * 2013-02-28 2015-10-14 成都创宜生物科技有限公司 一种检测胎膜早破免疫层析试纸的制备方法
CN103235134B (zh) * 2013-05-08 2015-10-14 成都创宜生物科技有限公司 一种检测胎膜早破的免疫层析试纸及其制备方法
CN103698537A (zh) * 2014-01-06 2014-04-02 天津医科大学总医院 定量检测人血清可溶性细胞间粘附分子-1的化学发光免疫分析试剂盒及检测方法
JP2021514678A (ja) * 2018-03-06 2021-06-17 ペップバックス・インコーポレイテッド 核酸分子およびそれを使用する方法

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4769330A (en) 1981-12-24 1988-09-06 Health Research, Incorporated Modified vaccinia virus and methods for making and using the same
US4603112A (en) 1981-12-24 1986-07-29 Health Research, Incorporated Modified vaccinia virus
IL73534A (en) 1983-11-18 1990-12-23 Riker Laboratories Inc 1h-imidazo(4,5-c)quinoline-4-amines,their preparation and pharmaceutical compositions containing certain such compounds
FR2643817B1 (fr) 1989-03-06 1993-12-17 Transgene Sa Composition pharmaceutique, utile a titre preventif ou curatif contre les tumeurs induites par les papillomavirus
FR2602790B1 (fr) * 1986-08-13 1990-06-01 Transgene Sa Expression d'un antigene specifique de tumeur par un virus vecteur recombinant et utilisation de celui-ci pour le traitement preventif ou curatif de la tumeur correspondante
DE3642912A1 (de) 1986-12-16 1988-06-30 Leybold Ag Messeinrichtung fuer paramagnetische messgeraete mit einer messkammer
US6222020B1 (en) 1987-01-07 2001-04-24 Imperial Cancer Research Technology Limited Antigens derived from the core protein of the human mammary epithelial mucin
ATE128727T1 (de) 1987-05-04 1995-10-15 Dana Farber Cancer Inst Inc Interzellulare adhäsions-moleküle und deren bindungsliganden.
FR2632863B2 (fr) 1987-10-29 1990-08-31 Transgene Sa Virus du fowlpox recombinant et vaccins derives de ces virus
CA2008368C (en) 1989-01-24 2003-04-08 Jeffrey Greve Soluble molecule related to but distinct from icam-1
US5100587A (en) 1989-11-13 1992-03-31 The United States Of America As Represented By The Department Of Energy Solid-state radioluminescent zeolite-containing composition and light sources
FR2668064B1 (fr) 1990-10-23 1994-12-16 Transgene Sa Composition pharmaceutique pour le traitement ou la prevention d'une tumeur maligne.
US5756102A (en) 1990-11-20 1998-05-26 Virogenetics Corporation Poxvirus-canine distemper virus (CDV) recombinants and compositions and methods employing the recombinants
US5389640A (en) 1991-03-01 1995-02-14 Minnesota Mining And Manufacturing Company 1-substituted, 2-substituted 1H-imidazo[4,5-c]quinolin-4-amines
DE69233158T2 (de) 1991-03-07 2004-05-13 Connaught Technology Corp., Greenville Gentechnologisch hergestellter stamm für impfstoffe
US5179993A (en) 1991-03-26 1993-01-19 Hughes Aircraft Company Method of fabricating anisometric metal needles and birefringent suspension thereof in dielectric fluid
US6013638A (en) 1991-10-02 2000-01-11 The United States Of America As Represented By The Department Of Health And Human Services Adenovirus comprising deletions on the E1A, E1B and E3 regions for transfer of genes to the lung
US6133028A (en) 1993-05-28 2000-10-17 Transgene S.A. Defective adenoviruses and corresponding complementation lines
FR2705686B1 (fr) 1993-05-28 1995-08-18 Transgene Sa Nouveaux adénovirus défectifs et lignées de complémentation correspondantes.
US5698443A (en) 1995-06-27 1997-12-16 Calydon, Inc. Tissue specific viral vectors
US20030026782A1 (en) 1995-02-07 2003-02-06 Arthur M. Krieg Immunomodulatory oligonucleotides
ATE509102T1 (de) 1994-07-15 2011-05-15 Univ Iowa Res Found Immunomodulatorische oligonukleotide
US6638762B1 (en) 1994-11-28 2003-10-28 Genetic Therapy, Inc. Tissue-vectors specific replication and gene expression
US5998205A (en) 1994-11-28 1999-12-07 Genetic Therapy, Inc. Vectors for tissue-specific replication
FR2727689A1 (fr) 1994-12-01 1996-06-07 Transgene Sa Nouveau procede de preparation d'un vecteur viral
IL116816A (en) 1995-01-20 2003-05-29 Rhone Poulenc Rorer Sa Cell for the production of a defective recombinant adenovirus or an adeno-associated virus and the various uses thereof
SI0833934T2 (sl) 1995-06-15 2013-04-30 Crucell Holland B.V. Pakirni sistemi za humani rekombinantni adenovirus za uporabo v genski terapiji
CA2261989C (en) 1996-07-25 2008-09-30 Therion Biologics Corporation Recombinant pox virus for immunization against tumor-associated antigens
FR2751879B1 (fr) 1996-07-30 1998-10-30 Transgene Sa Composition pharmaceutique contre les tumeurs et infections a papillomavirus
EP1012276A2 (en) 1997-02-24 2000-06-28 Therion Biologics Corporation Recombinant pox virus for immunization against muc1 tumor-associated antigen
FR2766091A1 (fr) 1997-07-18 1999-01-22 Transgene Sa Composition antitumorale a base de polypeptide immunogene de localisation cellulaire modifiee
US6110929A (en) 1998-07-28 2000-08-29 3M Innovative Properties Company Oxazolo, thiazolo and selenazolo [4,5-c]-quinolin-4-amines and analogs thereof
US6900049B2 (en) 1998-09-10 2005-05-31 Cell Genesys, Inc. Adenovirus vectors containing cell status-specific response elements and methods of use thereof
US20020037274A1 (en) 1998-10-26 2002-03-28 Angelica Williams Single agent method for killing tumor and tumor associated endothelial cells using adenoviral mutants
FR2787465A1 (fr) 1998-12-21 2000-06-23 Transgene Sa Procede d'inactivation des virus enveloppes dans une preparation virale de virus non enveloppes
CA2362367C (en) 1999-02-04 2004-08-03 Geron Corporation Telomerase reverse transcriptase transcriptional regulatory sequences
EP1155120B1 (fr) 1999-02-22 2006-07-05 Transgene S.A. Procede d'obtention d'une preparation virale purifiee
US6492169B1 (en) 1999-05-18 2002-12-10 Crucell Holland, B.V. Complementing cell lines
US6331539B1 (en) 1999-06-10 2001-12-18 3M Innovative Properties Company Sulfonamide and sulfamide substituted imidazoquinolines
ES2288488T3 (es) 1999-11-15 2008-01-16 Onyx Pharmaceuticals, Inc. Adenovirus oncoliticos.
AUPQ520800A0 (en) 2000-01-21 2000-02-17 Alfred Hospital Prime-boost vaccination strategy
PL212047B1 (pl) 2000-11-23 2012-08-31 Bavarian Nordic As Zmodyfikowany wirus krowianki szczepu Ankara MVA-BN i jego pochodna, genom i zawierające je kompozycja farmaceutyczna, zwłaszcza szczepionka oraz ich zastosowania
GB0118532D0 (en) 2001-07-30 2001-09-19 Isis Innovation Materials and methods relating to improved vaccination strategies
PT2241325E (pt) 2002-10-29 2012-04-12 Coley Pharm Gmbh Utilização de oligonucleótidos cpg no tratamento de infecção com vírus da hepatite c
FR2855758B1 (fr) 2003-06-05 2005-07-22 Biomerieux Sa Composition comprenant la polyproteine ns3/ns4 et le polypeptide ns5b du vhc, vecteurs d'expression incluant les sequences nucleiques correspondantes et leur utilisation en therapeutique
FR2862648B1 (fr) 2003-11-21 2006-02-03 Biomerieux Sa Nouveau peptide immunogene et nouveaux epitopes et utilisations notamment dans la preparation de compositions pharmaceutiques actives contre le virus de l 'hepatite c
US7381536B2 (en) 2005-03-01 2008-06-03 Gurbel Paul A Assessment of cardiac health and thrombotic risk in a patient

Similar Documents

Publication Publication Date Title
Wang et al. Pulmonary fibrosis: pathogenesis and therapeutic strategies
Bergis et al. High serum levels of the interleukin-33 receptor soluble ST2 as a negative prognostic factor in hepatocellular carcinoma
Peng et al. Advances of cancer-associated fibroblasts in liver cancer
Villa et al. Dynamic angiopoietin-2 assessment predicts survival and chronic course in hospitalized patients with COVID-19
Xia et al. Golgi protein 73 and its diagnostic value in liver diseases
He et al. High expression of trimethylated histone H3 lysine 4 is associated with poor prognosis in hepatocellular carcinoma
Hiraoka et al. Soluble CD163 in patients with liver diseases: very high levels of soluble CD163 in patients with fulminant hepatic failure
Lin et al. Neuropilin 1 (NRP1) is a novel tumor marker in hepatocellular carcinoma
RU2013106940A (ru) Биомаркеры в плазме крови, предназначенные для комбинированных терапий с использованием бевацизумаба при лечении рака поджелудочной железы
Kim et al. Serum Dickkopf-1 as a biomarker for the diagnosis of hepatocellular carcinoma
BR112020004439A2 (pt) diagnóstico não invasivo de doenças de fígado gorduroso não alcoólico, esteato-hepatite não alcoólica e/ou fibrose de fígado
Chwist et al. A composite model including visfatin, tissue polypeptide-specific antigen, hyaluronic acid, and hematological variables for the diagnosis of moderate-to-severe fibrosis in nonalcoholic fatty liver disease: a preliminary study
Chen et al. Chinese herbal medicine suppresses invasion-promoting capacity of cancer-associated fibroblasts in pancreatic cancer
Hwang et al. Identification of anti-SF3B1 autoantibody as a diagnostic marker in patients with hepatocellular carcinoma
Zhang et al. A panel of autoantibodies against multiple tumor-associated antigens in the immunodiagnosis of esophageal squamous cell cancer
JP2012515893A5 (https=)
Sagar et al. The potential of PIVKA-II as a treatment response biomarker in hepatocellular carcinoma: a prospective United Kingdom cohort study
Liu et al. Metabolomics and proteomics reveal blocking argininosuccinate synthetase 1 alleviates colitis in mice
Fu et al. Clusterin contributes to hepatitis C virus-related hepatocellular carcinoma by regulating autophagy
JP2017538920A (ja) 血漿免疫標識物−ｖｅｇｆｒ１自己抗体の検出に用いる抗原ポリペプチド及び応用
HRP20150470T1 (hr) Topljivi icam-1 kao biomarker za predviđanje terapijskog odgovora
JP2016095233A (ja) 早期肝細胞がん患者の再発リスクの予測を補助する方法、システム及びコンピュータプログラム製品
Yang et al. LINC00703 acts as a tumor suppressor via regulating miR-181a/KLF6 axis in gastric cancer
JP2012521549A5 (https=)
Liu et al. Eradication of EGFR-positive circulating tumor cells and objective tumor response with lapatinib and capecitabine